AMRX
Amneal Pharmaceuticals, Inc.
20.30$
-0.3%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 39.5% | 39.7% | 39.9% | 42.3% | 43.7% | 45.3% | 44.9% | 46.3% | 51.1% | 52.0% | 50.8% | 51.6% | |
| 2.4% | 2.6% | 1.4% | 1.2% | 2.1% | 3.2% | 1.8% | 2.4% | 5.6% | 8.5% | 5.6% | 3.4% | |
| 2.5% | 2.7% | 1.4% | 1.3% | 2.1% | 3.2% | 1.8% | 2.4% | 5.6% | 8.5% | 5.6% | 3.4% | |
| 18.7% | 18.6% | 20.4% | 22.9% | 22.7% | 22.2% | 23.8% | 24.8% | 25.7% | 25.6% | 25.5% | 27.0% | |
| 15.6% | 16.7% | 16.5% | 16.4% | 17.2% | 17.5% | 17.9% | 17.8% | 17.1% | 16.5% | 18.1% | 18.0% | |
| 16.2% | 17.2% | 17.3% | 17.1% | 17.3% | 17.1% | 17.8% | 17.5% | 16.6% | 16.2% | 16.8% | 15.7% | |
| 26.6% | 25.6% | 24.9% | 23.4% | 22.5% | 20.9% | 20.5% | 19.0% | 16.3% | 15.3% | 15.1% | 15.6% | |
| 94.8% | 98.2% | 100.5% | 100.1% | 101.0% | 101.3% | 101.8% | 101.4% | 103.1% | 99.8% | 101.3% | 96.9% | |
| 20.6% | 24.4% | 24.1% | 31.7% | 31.6% | 32.3% | 32.0% | 32.3% | 23.9% | 24.0% | 20.6% | 23.4% | |
| 3.3% | 6.6% | 6.6% | 12.9% | 11.0% | 9.7% | 10.0% | 9.8% | 0.6% | 0.6% | 0.6% | 3.2% | |
| 4.8% | 4.1% | 5.1% | 5.7% | 6.8% | 7.4% | 5.7% | 19.5% | 7.4% | 6.9% | 6.4% | 6.5% | |
| 70.1% | 69.9% | 70.0% | 62.0% | 62.7% | 61.7% | 64.0% | 62.7% | 71.3% | 69.7% | 72.5% | 67.9% | |
| 9.0% | 0.6% | -1.8% | -1.6% | -2.7% | -3.1% | -3.9% | -3.3% | -3.0% | -1.9% | -1.3% | 0.9% | |
| -10.6% | -14.1% | -16.8% | -16.4% | -16.6% | -17.3% | -17.7% | -16.7% | -15.8% | -14.5% | -13.4% | -11.0% | |
| 4.3% | 7.0% | 8.9% | 9.1% | 8.9% | 8.8% | 9.6% | 9.4% | 9.0% | 8.8% | 9.3% | 8.7% |
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.